EP
Ek Pharma
This pharmaceutical R&D company focuses on developing innovative anti-cancer drugs and advanced drug formulations. The core technology involves screening anti-cancer drugs targeting the novel target DNA replication initiation protein (DRIPs). The company is advancing its first-in-class DRIPs inhibitor, EN002 gel, through clinical trials for skin cancer treatment, alongside developing liposome inhalation formulations for respiratory diseases.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This pharmaceutical R&D company focuses on developing innovative anti-cancer drugs and advanced drug formulations. The core technology involves screening anti-cancer drugs targeting the novel target DNA replication initiation protein (DRIPs). The company is advancing its first-in-class DRIPs inhibitor, EN002 gel, through clinical trials for skin cancer treatment, alongside developing liposome inhalation formulations for respiratory diseases.